_undetectable-minimal-residual-disease-umrd-explained-preview-1.jpg "Undetectable Minimal Residual Disease (UMRD) Explained from umrd Video Screenshot Preview 1")
Gallery_undetectable-minimal-residual-disease-umrd-explained-preview-3.jpg "Undetectable Minimal Residual Disease (UMRD) Explained from umrd Video Screenshot Preview 3")
Gallery_undetectable-minimal-residual-disease-umrd-explained-preview-hqdefault.jpg "Undetectable Minimal Residual Disease (UMRD) Explained from umrd Video Screenshot Preview hqdefault")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Jump To Video Parts
⏲ Duration: 1 minute 30 seconds
👁 View: 62 times
Play Audio:👁 View: 62 times
Description:
Patient Empowerment Network
Patient Empowerment Network
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
Related Videos
_undetectable-minimal-residual-disease-umrd-explained.webp "Dr. Brian Koffman, co-founder of The CLL Society, defines the term undetectable minimal residual disease (UMRD) and explains its role in chronic lymphocytic leukemia (CLL) care.nnDr. Brian Koffman is the cofounder, chief medical officer, and executive vice president of The CLL Society.")
_captivate-study-outcomes-in-patients-with-umrd-following-cessation-of-ibrutinib-plus-venetoclax.webp "VJHemOnc – Video Journal of Hematology u0026 HemOnc")
⏲ 1 minute 34 seconds 👁 49
_icll07-filo-study-minimal-residual-disease-still-detectable-after-first-line-combination-therapy.webp "Prof Feugier speaks with ecancer at EHA 23 about results from a phase II trial of treating CLL with induction obinutuzumab and ibrutinib.nnHe describes how CR with undetectable residual disease (uMRD) may be associated with a longer survival in CLL.nnWith a manageable toxicity profile, 48% CR rate and 12.5% uMRD at 9 months, Prof Feugier describes the need for further research and further rounds of immunochemotherapy to fully induce uMRD.")
⏲ 2 min 20 sec ✓ 17-Jun-2018
_captivate-ibrutinib-venetoclax-delivers-high-rates-of-umrd-in-cll.webp "VJHemOnc – Video Journal of Hematology u0026 HemOnc")
_liso-cel-induces-rapid-umrd-transcend-cll-004-update.webp "VJHemOnc – Video Journal of Hematology u0026 HemOnc")
_undetectable-minimal-residual-disease-umrd-explained.jpg)
_captivate-study-outcomes-in-patients-with-umrd-following-cessation-of-ibrutinib-plus-venetoclax.jpg)
_icll07-filo-study-minimal-residual-disease-still-detectable-after-first-line-combination-therapy.jpg)
_captivate-ibrutinib-venetoclax-delivers-high-rates-of-umrd-in-cll.jpg)
_liso-cel-induces-rapid-umrd-transcend-cll-004-update.jpg)
![[+]](/images/menu.gif){kind=small}